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Abstract 
Background: To compare the use of Memantine with Dextromethorphan and 
placebo to reduce pain after orthopedic surgery.  
Materials and Methods: The present study was a double-blind clinical trial 
including180 patients undergoing elective orthopedic surgery of the lower 
limbs. Patients were divided randomly into three groups of 60 patients each. 
The first group (Group M) received 30 mg Memantine orally, the second 
group (Group D) received 45 mg of Dextromethorphan and the third group 
(Group P) received only placebo, two and a half hours before the operation. 
The intensity of pain (VAS score), sedation score, and nausea and vomiting 
were recorded postoperatively.  
Results: In this study, 60 patients were enrolled in each group. The total 
VAS (Visual Analogue Scale) score was significantly lower among patients 
receiving Memantine and the satisfaction was significantly higher compared 
to the Dextromethorphan and placebo groups (P-value <0.001).  
Conclusion: The present study results indicate that Memantine has a 
relatively better outcome compared to Dextromethorphan or placebo in 
reducing the post-surgical pain among patients undergoing orthopedic 
surgeries. It also reduced the need for post-surgical opioid use and improved 
the patients’ satisfaction.  
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Introduction 
Pain is defined by the International Association 
for the Study of Pain as an unpleasant sensory and 
emotional experience associated with actual or 
potential tissue damage or described in terms of such 
damage (1). Acute post surgical pain is one of the 
most important complications of any surgical 
procedure and may increase perioperative mortality 
rate. Post operative pain has negative effects on 
various body systems such as respiratory, 
cardiovascular, gastrointestinal and urinary systems 
and causes metabolic, neurological, and hormonal 
changes (2). Methods of reducing acute pain after 
surgery, including preoperative administration of 
analgesics as well as central and peripheral nerve 
blocks, each have their usage in reducing the post 
operative pain. One of pain management procedures 
to control acute postoperative pain is the use of 
medical interventions (3, 4).  
N-methyl-D-aspartate (NMDA) is a receptor for 
glutamate neurotransmitter, which is released 
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following a painful stimulus.  NMDA is in fact one of 
several important receptors for rapid transmission in 
central nervous system and plays an important role in 
the central sensitization phenomenon (5). Activation 
of NMDA receptors causes hyperalgesia, neuropathic 
pain and reduction of opioid receptors’ activity. 
Hyperalgesia and neuropathic pain are due to increase 
in spinal nerves sensitivity causing higher levels of 
pain. Reduction in activity of opioid receptors is 
associated with a decline in their sensitivity. The 
decrease in sensitivity is known as opioid tolerance 
and means there is a need for a higher dose to achieve 
the effects of treatment. So NMDA antagonists can 
have a role in pain control (6,7), and combined use of 
opioids and NMDA antagonists will increase the 
efficacy of opioids and decrease the drug resistance 
(8). There are different sites for NMDA antagonists to 
bind and the differences in their potency have been 
attributed to the difference in binding site and the 
affinity of the receptors (6, 7). Several studies have 
shown that NMDA receptor antagonists might have a 
role in somatic as well as acute and chronic visceral 
pain control (9, 10).  
NMDA receptor antagonists include Ketamine, 
Methadone, Memantine, Amantadine and 
Dextromethorphan. Ketamine is a strong receptor 
antagonist for this receptor. The severity and 
frequency of adverse symptoms depends on the 
affinity of drug to NMDA receptor and these 
symptoms manifest mainly in the central nervous 
system in the form of hallucinations, lightheadedness, 
fatigue, confusion, nightmares, headaches and sensory 
changes in adults, which is more severe when using 
Ketamine (11, 12). 
Memantine is another oral NMDA receptor antagonist 
which has a non-competitive moderate affinity for 
this receptor with a rapid onset and fewer side effects. 
Previous studies have shown that this drug, when 
administered prior to nerve damage, has the ability to 
reduce the neuropathic pain (13, 14). Memantine was 
synthesized for the first time in 1960 and after clinical 
trials in Germany was used in treatment of dementia, 
brain diseases and Parkinson disease in the late 1980s. 
Also after receiving approval from Food and Drug 
Administration in 2003 this drug is widely used in 
treatment of Alzheimer's disease, but its use in 
treatment of chronic pain is relatively new. This drug 
is different from the first-generation NMDA receptor 
antagonists like Ketamine since it is better tolerated 
and causes less hallucinogenic side effects. Several 
differences may explain why these drugs are 
significantly different when comparing their clinical 
side effects. The elimination half-life of Memantine is 
60-80 hours compared to a half-life of 2.5 hours for 
oral or intravenous Ketamine. Faster 
pharmacokinetics of Ketamine may lead to a sharp 
increase in drug serum levels and possibly 
psychotomimetic effects (13-17). 
Previous studies had indicated that Memantine might 
be effective in analgesia, so it was first used in 
patients with post-surgical neuropathic pain. There is 
a potential benefit for early treatment, since NMDA 
channels show a post-surgical increase in activity and 
might cause neuropathic pain (18,19).  
Dextromethorphan and its metabolites are non-
competitive NMDA receptor antagonists with low 
afinity (20). Dextromethorphan is a synthetic 
derivative of narcotics, but with no narcotic effect 
(21). Dextromethorphan has a long history of safe 
use, and it seems that if used in the period 
immediately before surgery, it reduces the need for 
analgesic drugs in the post surgical period (22, 23). 
In recent years the use of preemptive analgesia has 
increased worldwide and with substantial progress in 
understanding pain mechanisms, new therapeutic 
concepts have emerged. Studies have shown that 
sensitization of neurons in the dorsal horn of spinal 
cord after tissue damage, leads to hyperalgesia or 
allodynia and this process plays a key role in 
development of chronic pain after a painful 
stimulation. Thereby reducing the over-stimulation of 
neurons in the dorsal horn of the spinal cord, with 
starting the analgesic treatment before tissue damage 
such as surgical incision, is necessary to reduce the up 
regulation of central nervous system which is the 
concept of preemptive analgesia (24).  
Numerous studies about the benefits of preemptive 
analgesia, especially in the last 10 years, have been 
conducted and all of them have confirmed its benefit. 
These studies suggest that preemptive analgesia has 
three objectives: a) reduce the pain caused by the 
activation of inflammation mechanisms following 
surgical incision, b) prevent the call memory of the 
central nervous system to pain, and c) ensure 
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adequate control of postoperative pain to avoid the 
spread of chronic pain (24). 
Preemptive analgesia is an intervention performed 
before the surgical incision to reduce the 
establishment of central sensitization and 
consequently reduces the inflammatory and incisional 
damage during and after the surgery. The preemptive 
analgesia can hypothetically prevent the hyperalgesia 
as well as acute and chronic postoperative pain by 
reducing the sensitization of central nervous system 
(24). 
The main objective of the present study was to 
compare the effect of Memantine with 
Dextromethorphan and placebo in reducing pain after 
elective orthopedic surgery. 
Methods 
In this prospective study, 180 patients 
undergoing elective orthopedic surgery of the lower 
limbs (calf fracture) aged 18-65 years and physical 
health status of ASA 1 or 2 were selected and 
randomly divided into three groups of 60 people each. 
All patients were visited before and after surgery by 
an anesthesiologist and entered the study after giving 
written informed consent. This study was approved by 
the ethics committee of Shahid Beheshti University of 
Medical Sciences, Tehran, Iran (sbmu.rec.1393.552). 
The study was also registered in Iranian Registry of 
Clinical Trials (IRCT2017062413364N4).  
Group (M) received 30 mg oral Memantine 
group (D) received 45 mg Dextromethorphan and the 
group (P) was given placebo, about two and a half 
hours before the start of operation. Only the physician 
responsible for treatment knew the drug each patient 
received. The patient and another physician tasked 
with documenting the post-surgical pain score, the 
need for analgesics and the patients’ satisfaction, were 
blinded to the drug received by the patient. 
The exclusion criteria were ASA physical 
health status of 3 or 4, diseases of the respiratory 
system, heart, brain and endocrine glands, any drug 
consumption in one week prior to surgery, sensitivity 
to drugs used in the study, a history of mental illness, 
MAOIs or SSRIs during 4 weeks before the surgery, 
pregnancy, a history of stroke and finally type 1 and 2 
diabetes mellitus. Also all patients developing 
compartment syndrome were excluded from the 
study. 
All patients went under spinal anesthesia using 
a number 25 spinal needle and Bupivacaine 0.5 
percent.  Patients were transferred to recovery after 
the conclusion of surgery and their VAS score was 
documented after the return of lower limbs sensation. 
At this time intravenous PCA pump containing 
morphine at a concentration of 2.0 mg per ml and 
transfer rate of 4 ml per hour and a bolus dose of 5.0 
ml every 15 minutes was used to control patients’ 
pain. If the patient had a VAS (Visual Analogue 
Scale) score of over 4 in the recovery or anytime till 
48 hours after the surgery, they would receive a 4mg 
dose of Morphine and the total dose of Morphine was 
documented. Also at the end of 48 hours the total 
amount of drugs consumed through intravenous PCA 
pump was recorded for each patient. The intensity of 
pain (VAS), sedation score, and nausea and vomiting 
were recorded 6, 12, 24, 36 and 48 hours after the 
surgery. 
The pain score was assessed on the basis of 
VAS score, by displaying a scaled ruler to the patient, 
so that zero equaled no pain and 10 equaled the 
maximum imaginable pain for patients. 
Sedation scores were classified as follow: 0 for 
restless, 1 for quiet, 2 for sleepy, 3 for       confused 
but with respond to verbal commands, 4 for no 
response to verbal commands, and 5 for no response 
to painful stimulus. 
Measurement of nausea and vomiting were as 
follow: 0 for no nausea and vomiting, 1 for mild 
nausea without the need for medication, 2 for nausea 
needing medication, 3 for nausea and lack of response 
to anti-nausea drugs. 
At the end of 48 hours post operation patient 
satisfaction during this period was evaluated based on 
the following criteria: 0 for absolutely no pain, 1 for 
sometimes moderate pain, 2 for always moderate 
pain, 3 for sometimes severe pain, 4 for always 
moderate pain and sometimes severe pain, and  5 for 
always severe pain. 
Results 
In the present study, 60 patients were enrolled 
in each group. There was not a significant difference 
between three groups regarding age and sex (Table 1). 
Also the type of surgery had no meaningful difference 
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among the three groups. 
The mean VAS score was significantly 
different among the three groups of patients and was 
significantly lower in group M compared to group D 
and group P (P-value <0.001). But this difference was 
not significant between groups D and P. 
The following chart shows changes in VAS score 
within 48 hours after the surgery. As it can be 
observed the pain was lower in Memantine group 
compared to the other two groups. 
Table 2 shows the percentage of quiet and 
restless patients in the three groups. As it can be 
observed at 6, 12 and 24 hours after the surgery the 
percent of restless patients was significantly lower in 
group M compared to group D, but this difference 
was not statistically significant 36 and 48 hours after 
the surgery.  
In 6 and 12 hours post-surgery the number of 
patients with nausea was lower in group M compared 
to group D and P, but this difference was not 
significant in other post-surgical intervals. When 
comparing the overall satisfaction among patients at 
the end of 48 hours post-surgery the overall 
satisfaction was significantly higher in group M 
compared to groups D and P. There was no significant 
difference in overall satisfaction between D and P 
groups (Table 3, Figure 2). 
Also the total use of opioid during 48 hours 
post-surgery was lower in group M compared to 
group D and P (Table 4, Figure 3). 
Discussion 
The present study showed that the rate of post-
operative pain in group M was lower than group D. 
Interestingly in group M the pain within 48 hours was 
significantly lower than Group D, but the difference 
was more significant during the first 24 hours. This 
might be due to the half-life of the drugs which makes 
them less effective after 24 hours. 
It should be noted that Memantine as a NMDA 







































Figure 1. VAS changes in the first 48 hours after the 
surgery in three groups of patients entering the study.  
Figure 2. Satisfaction among patients at the end of 48 
hours post-surgery. 
 
Figure 3. The total use of opioid during 48 hours post-
surgery in three groups of patients entering the study. 
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antagonist has been used in treatment of many 
neuropathic pains, but its use in the treatment of acute 
postoperative pain is not widespread. Oral Memantine 
has a bioavailability of about 40% and it takes 24 
hours to reach a constant plasma level. After a single 
oral dose the drug reaches Cmax within 6 hours and it 
has a half-life of 60 to 100 hours. If used as a skin 
patch it has greater bioavailability of approximately 
60% and provides adequate plasma levels for several 
days (25).  
NMDA receptors increase the plasticity of 
synapses. Only synapses with active NMDA can 
create plasticity and neuronal pain memory in 
response to entrance of Ca after unblocking of Mg ++ 
(26).  
Memantine has been indicated to reduce the 
post-surgical pain in several studies (27). In our study 
Memantine showed a good potency to reduce the pain 
during the 48 hours after the surgery, which was 
significantly better than Dextromethorphan. In fact, 
Dextromethorphan did not significantly reduce the 
postoperative pain. Dextromethorphan is a non-
competitive antagonist of NMDA receptor with low 
affinity to these receptors while Memantine has a 
higher affinity for NMDA receptors, so the difference 
in analgesic effect of these two drugs is likely to be 
due to their different affinity for NMDA receptors. 
Numerous studies have indicated that Memantine 
administered after surgery can reduce the chance of 
chronic post-surgical pain and also prevent phantom 
Table 2: The percentage of quiet and restless patients in the three groups entering the study. 
 







6h    <0.001 
Restless 58 (96.7%) 37 (61.7%) 59 (98.3%)  
Quiet 2 (3.3%) 23 (38.3%) 1 (1.7%)  
12h    0.001 
Restless 33 (55.0%) 14 (23.3%) 17 (28.3%)  
Quiet 27 (45.0%) 46 (76.7%) 43 (71.7%)  
24h    <0.001 
Restless 13 (21.7%) 2 (3.3%) 2 (3.3%)  
Quiet 47 (78.3%) 58 (96.7%) 58 (96.7%)  
36h    0.129 
Restless 4 (6.7%) 1 (1.7%) 0 (0.0%)  
Quiet 56 (93.3%) 59 (98.3%) 60 (100.0%)  
48h    >0.999 
Restless 0 (0.0%) 1 (1.7%) 1 (1.7%)  
Quiet 6 (100.00%) 59 (98.3%) 59 (98.3%)  
Total    <0.001 
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pain after amputation (28-31). 
A previous study has indicated that the use of 
Dextromethorphan syrup 2 to 3 hours before the knee 
arthroscopic surgery reduces the pain and the need for 
opioids in first 8 post-surgical hours (8), which is 
similar to our findings, but the present study indicated 
that Memantine had a better outcome in reducing the 
post-surgical pain compared to Dextromethorphan. 
In this study, postoperative nausea and vomiting was 
significantly lower in Memantine group compared to 
Dextromethorphan group in the first 12 hours after 
surgery.We also found that after using Memantine the 
first patient’s request for opioid is delayed and also 
the total post-surgical opioid usage is lower compared 
to Dextromethorphan or placebo, which can explain 
the lower incidence of opioid side effects like nausea 
and vomiting.  
It should be noted that in the present study 
Memantine resulted in significantly higher patient 
satisfaction, lower post-surgical pain scores and less 
need for post-surgical opioid use compared to 
placebo, but there was no difference between placebo 
and Dextromethorphan.  Also the overall satisfaction 
was higher when comparing Memantine and 
Dextromethorphan. 
Conclusion 
The present study results indicate that 
Memantine has a relatively better outcome compared 
to Dextromethorphan or placebo in reducing the pain 
among patients undergoing orthopedic surgeries. It 
also reduced the need for post-surgical opioid use and 
improved the patients’ satisfaction. 
 














Median (IQR) 2 (1-2) 1 (0-1) 2 (2-2) <0.001 <0.001 0.699 <0.001 
0: Absolutely no pain 0 (0.0%) 17 (28.3%) 0 (0.0%)     
Sometimes  moderate 
pain 
17 (28.3%) 37 (61.7%) 12 (20.0%)     
2- Always moderate 
pain 
34 (56.7%) 5 (8.3%) 42 (70.0%)     
3- Sometimes severe 
pain 
9 (15.0%) 1 (1.7%) 6 (10.0%)     
4: Always moderate 
pain and sometimes 
severe pain 
0 (0.0%) 0 (0.0%) 0 (0.0%)     
5: Always severe pain 0 (0.0%) 0 (0.0%) 0 (0.0%)     
 
* P1= P-value for difference between Group D and M 
P2= P-value for difference between Group D and P 
P3= P-value for difference between Group M and P 
 














The total use of 
opioid in 48 
hours post-
surgery 
47.17±4.05 38.18±4.30 52.28±2.94 <0.001 <0.001 <0.001 <0.001 
 
* P1= P-value for difference between Group D and M 
P2= P-value for difference between Group D and P 
P3= P-value for difference between Group M and P 
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